Company Insights

SCLXW supplier relationships

Explore interactive graphBrowse insights index
SCLXW supplier relationship map

Scilex Holding Company (SCLXW): Supplier Map, Contract Profile and Investor Implications

Scilex Holding Company operates as a revenue-generating biopharmaceutical platform that acquires, develops and commercializes non‑opioid pain therapies, monetizing through product sales of commercial assets (ZTlido, ELYXYB, GLOPERBA) and licensing arrangements. The company’s go‑to‑market relies on a distributed manufacturing and logistics network: third‑party contract manufacturers supply finished product and excipients, while large pharmaceutical distributors handle U.S. distribution — a structure that reduces fixed manufacturing capital but imports concentration and counterparty risk into the P&L. For a deeper supplier‑level view and sourcing intelligence visit https://nullexposure.com/.

Why suppliers matter more than a balance sheet here

Scilex reports $40.36 million in trailing revenue but negative operating margins, and the business model is operationally dependent on external manufacturers and distributors. That operating posture defines cash flow volatility: inventory and supplier disruption can directly curtail sales even when demand exists. Key investment questions therefore center on single‑source exposure, contract duration and the ability to switch partners without clinical or regulatory delay.

The supplier roster, one page for investors

Below I walk through every supplier and partner cited in the public record for SCLXW, with one‑line takeaways and concise sourcing.

AmerisourceBergen Corporation

AmerisourceBergen is one of the pharmaceutical distributors Scilex contracts with for U.S. distribution of commercial products. According to Scilex’s FY2024 Form 10‑K, the company “contracts with multiple pharmaceutical distributors … including … AmerisourceBergen.” (FY2024 10‑K).

Cardinal Health 105, LLC

Cardinal Health 105 is named as Scilex’s exclusive third‑party logistics distribution provider in the United States, responsible for temperature‑controlled shipments from production to customer distribution centers. This is documented in the FY2024 10‑K where Cardinal Health 105 is described as the third‑party logistics provider (FY2024 10‑K).

Contract Pharmaceuticals Ltd Canada (CPL)

CPL is identified as the sole supplier for ELYXYB inventory purchases initiated in November 2023, indicating single‑source supply for that product. The FY2024 10‑K states the company began purchasing ELYXYB inventories from CPL in late 2023 (FY2024 10‑K).

Ferndale Laboratories, Inc.

Ferndale is listed as the sole supplier for GLOPERBA inventory purchases started in February 2024, again highlighting product‑level supplier concentration. The FY2024 10‑K notes the commencement of purchases from Ferndale in early 2024 (FY2024 10‑K).

Genzyme

Genzyme historically supplied sodium hyaluronate (an excipient for SP‑102) under a supply agreement that terminated May 31, 2024, removing a previously key supplier relationship. The FY2024 10‑K records that historical supply agreement and its termination date (FY2024 10‑K).

Itochu

Itochu is a manufacturer/supplier of lidocaine tape products and was a ZTlido inventory supplier; Scilex records foreign exchange losses on payments to Itochu, underlining both single‑source and FX exposure. This relationship and related FX loss are described in the FY2024 10‑K (FY2024 10‑K).

Itochu Chemical Frontier Corporation

Itochu Chemical Frontier Corporation is specifically referenced as Scilex’s sole ZTlido inventory supplier during the 2023–2024 period, and Scilex records revenue net of distributor and rebate reserves tied to such supply and distribution economics. The FY2024 10‑K contains these disclosures (FY2024 10‑K).

Tulex Pharmaceuticals Inc.

Tulex is the contract manufacturer identified as manufacturing product (location: Cranbury, NJ) under a master services agreement that was novated to legacy Scilex; the agreement has multi‑year duration referenced in the filings. The FY2024 10‑K cites Tulex as the contract manufacturer (FY2024 10‑K).

Datavault AI Inc.

Datavault AI is a partner named in Scilex’s November 3, 2025 press release about sponsoring the Dream Bowl 2026 and distributing a meme coin to shareholders, indicating a non‑core promotional/marketing relationship publicized via Globe Newswire on November 3, 2025 (Globe Newswire / Sahm Capital release, Nov 3, 2025).

McKesson Corporation

McKesson is one of the national pharmaceutical distributors that Scilex contracts with for U.S. distribution alongside Cardinal and AmerisourceBergen, per the FY2024 10‑K disclosure (FY2024 10‑K).

StockBlock Securities LLC

StockBlock Securities LLC acted as an exclusive placement agent (alongside Rodman & Renshaw) on financing transactions tied to exercise of warrants and equity offerings, referenced in press coverage of late‑2025 financing activity (news releases Nov 24–25, 2025).

Kasowitz LLP

Kasowitz LLP was appointed as Scilex’s litigation and intellectual property counsel in early‑2026 announcements, a signal that the company is actively reinforcing legal and IP support (news release covered in March 2026 press mentions).

Rodman & Renshaw LLC

Rodman & Renshaw LLC served as an exclusive placement agent with StockBlock Securities on financing transactions in late 2025, as described in company press releases and news summaries from November 2025.

Oishi

Oishi (Oishi Koseido Co., Ltd.) is the commercial manufacturer in Japan for ZTlido and is cited repeatedly as a single‑source manufacturer for lidocaine tape products under product development agreements; the FY2024 10‑K explicitly states ZTlido is commercially manufactured by Oishi in Japan (FY2024 10‑K).

What constraints reveal about operating risk and optionality

The public disclosures surface a consistent operating model signal:

  • Long‑term, licensing and manufacturing contracts dominate — Scilex uses licensing and multi‑year manufacturing agreements (e.g., Product Development Agreement, Tulex Master Services, Lifecore agreement) that structure supply stability but limit short‑term supplier substitution. Several of those contract excerpts name the counterparties (Tulex, Lifecore, Oishi) and therefore indicate contract maturity and duration attached to specific partners.
  • Material single‑source exposure is company‑level and product‑level — the SEC filing states dependence on contract manufacturers and identifies sole suppliers for ZTlido, ELYXYB and GLOPERBA; this is a material operational constraint and can translate directly into revenue risk if a supplier disruption occurs (company‑level signal from FY2024 10‑K).
  • Manufacturer and distributor roles are critical and concentrated — multiple excerpts list manufacturers (Oishi, Itochu, Tulex, Lifecore) and distributors (Cardinal Health 105, McKesson, AmerisourceBergen), creating two concentration layers: production and logistics.
  • Spend visibility includes meaningful recurring royalty payments — the filings disclose royalty payments of $8.3 million in each of 2023 and 2024, indicating a recurring outflow that investors should factor into cash needs (company‑level signal).

If you want a supplier risk scorecard and counterparty exposure breakdown for portfolio stress tests, start here: https://nullexposure.com/.

Investment implications and execution checklist

Scilex’s model efficiently leverages third‑party manufacturing and distribution to scale sales without heavy capital outlays, but that same architecture centralizes operational risk in a small set of suppliers and distributors. For active investors and operators evaluate:

  • Contract duration and termination flexibility with Oishi, Itochu, Tulex and Cardinal Health 105.
  • Inventory backup strategies for single‑source products (ELYXYB, GLOPERBA, ZTlido).
  • FX exposure controls tied to foreign manufacturers (e.g., Itochu) and the legal posture now that Kasowitz is engaged.

For detailed supplier profiles and to map supplier concentration into cash‑flow stress scenarios, visit the research hub at https://nullexposure.com/.

Bottom line: Scilex is a commercially active, asset‑light biopharma whose upside depends on execution across a small set of critical external manufacturers and distributors; investors should price in concentration risk and contractual rigidity when building valuation and liquidity assumptions. For ongoing monitoring of SCLXW supplier events and to receive supplier breach alerts register at https://nullexposure.com/.